List of Excipients in Branded Drug BUPRENEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Indivior Inc	BUPRENEX	buprenorphine hydrochloride	12496-0757	ANHYDROUS DEXTROSE
Indivior Inc	BUPRENEX	buprenorphine hydrochloride	12496-0757	HYDROCHLORIC ACID
Indivior Inc	BUPRENEX	buprenorphine hydrochloride	12496-0757	WATER

# BUPRENEX Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

BUPRENEX is an established buprenorphine hydrochloride injection with a simple parenteral formulation: buprenorphine hydrochloride, dextrose, water for injection, and hydrochloric acid for pH adjustment. Its core product is commercially mature, with limited composition-of-matter or exclusivity protection. The strongest opportunities are differentiated injectable presentations, container-closure systems, ready-to-administer delivery, preservative-free hospital packaging, and products that improve storage, handling, and medication safety.

What excipients are used in BUPRENEX injection?

BUPRENEX contains a minimal excipient system suitable for intramuscular and slow intravenous administration.

Component	Function	Commercial and technical relevance
Buprenorphine hydrochloride	Active pharmaceutical ingredient	Partial mu-opioid agonist used for opioid analgesia
Dextrose	Tonicity agent and formulation stabilizer	Supports a near-isotonic aqueous injection
Water for Injection	Vehicle	Sterile parenteral solvent
Hydrochloric acid	pH adjustment	Maintains acidic formulation conditions and supports drug solubility

BUPRENEX is supplied as a 0.3 mg/mL injection. The labeled formulation contains approximately 50 mg/mL dextrose, equivalent to a 5% dextrose solution. The label identifies hydrochloric acid as the pH-adjusting agent and does not identify an antimicrobial preservative.[1]

The product is administered by the intramuscular route or by slow intravenous injection. Its formulation is designed for immediate clinical use rather than extended multidose storage after opening.

Why does BUPRENEX use dextrose?

Dextrose provides tonicity control in the aqueous injection. At approximately 5%, dextrose contributes an osmolality broadly compatible with parenteral administration while avoiding the chloride load associated with sodium chloride-based systems.

Dextrose may also help maintain a consistent solution environment during storage. It does not, however, provide antimicrobial preservation. Sterility depends on manufacturing controls and single-use packaging.

What formulation constraints apply to buprenorphine hydrochloride?

Buprenorphine hydrochloride is a potent, low-dose opioid that requires precise concentration control. The formulation must address:

• Complete dissolution at low drug concentration.
• pH control sufficient to maintain solubility.
• Prevention of precipitation after dilution or admixture.
• Adsorption to glass, elastomeric closures, or delivery-device surfaces.
• Low particulate burden.
• Protection from oxidation and light where applicable.
• Accurate withdrawal from small-volume containers.
• Compatibility with intravenous administration equipment.

The acidic formulation environment is a material design constraint. A new product that changes pH, buffer capacity, or tonicity would require comparative stability, compatibility, safety, and administration data.

What is the FDA and Orange Book status of BUPRENEX?

BUPRENEX is an FDA-approved buprenorphine hydrochloride injection marketed under NDA 018401. The product has been approved for analgesic use in settings where an opioid analgesic is appropriate.[1]

The product is an old small-molecule injectable, not a biologic. Biosimilar pathways do not apply. Competition is based on generic drug approval, manufacturing reliability, hospital contracting, packaging, and clinical workflow rather than biosimilar interchangeability.

Regulatory item	BUPRENEX status
Active ingredient	Buprenorphine hydrochloride
Dosage form	Sterile injectable solution
Strength	0.3 mg/mL
FDA pathway	Original NDA
NDA	018401
Administration	Intramuscular and slow intravenous
Biologic status	Not applicable
Biosimilar exposure	None
Orange Book patent risk	No meaningful current composition patent barrier identified
Regulatory exclusivity	No current new-drug exclusivity expected for this mature product

The FDA Orange Book is the relevant source for listed patents and regulatory exclusivity. For a product approved in 1981, any original patent or regulatory exclusivity period has expired. Current competition therefore depends primarily on ANDA approvals and commercial execution.[2]

What patents protect BUPRENEX?

No commercially meaningful active-ingredient patent protection remains for buprenorphine hydrochloride injection. Buprenorphine was disclosed and developed decades ago, and the BUPRENEX NDA predates modern product-specific patent strategies.

The residual intellectual-property opportunity is in secondary protection.

Formulation patents

Potential formulation claims could cover:

• A defined pH range that improves stability.
• A specific dextrose concentration.
• A low-volume, high-concentration formulation.
• A formulation with reduced precipitation after dilution.
• A formulation with improved container compatibility.
• A formulation that eliminates visible particulates during storage.
• A formulation with a specified impurity profile.
• A formulation stable under refrigerated or controlled-room-temperature conditions.

These claims would face obviousness and written-description challenges because buprenorphine injection, aqueous acidic systems, dextrose tonicity adjustment, and sterile vial packaging are established technologies. A patent would be stronger if it tied the excipient combination to a measured, unexpected result, such as a substantial increase in shelf life, reduced degradation, improved recovery from a delivery device, or reduced precipitation under clinically relevant dilution conditions.

Method-of-use patents

Method-of-use patents could target:

• Acute postoperative pain.
• Emergency-department analgesia.
• Opioid-sparing perioperative protocols.
• Pain treatment in patients for whom longer-acting opioids create management problems.
• Specific dosing schedules or administration intervals.
• Use with selected patient populations.

Method-of-use protection would need a commercially meaningful label and credible clinical differentiation. Broad claims covering analgesia would be vulnerable because buprenorphine’s analgesic use is well established.

Device and packaging patents

Device-focused protection is more commercially practical than a broad excipient patent. Potential claims include:

• A prefilled syringe containing a defined buprenorphine formulation.
• A tamper-evident unit-dose package.
• A ready-to-administer syringe with controlled dose accuracy.
• A dual-component system that separates drug and diluent until use.
• A low-dead-space connector compatible with hospital infusion systems.
• Packaging that reduces opioid diversion or tampering.

These claims could support a 505(b)(2) product if the presentation, labeling, or clinical-use profile differs materially from the approved vial or ampule.

How strong is the BUPRENEX patent estate?

The BUPRENEX patent estate is weak as a blocking estate and potentially valuable as a platform for new product claims.

IP category	Current strength	Assessment
Composition of matter	Very low	Expired
Original product formulation	Very low	Mature formulation technology
Method of analgesic use	Low	Broad use is established
New excipient combination	Low to moderate	Requires unexpected technical effect
Container-closure system	Moderate	Stronger if linked to stability or dose accuracy
Prefilled syringe or autoinjector	Moderate	Commercially relevant but design-around risk exists
Manufacturing process	Moderate	Sterile processing and impurity control can create know-how
Trade secrets	Moderate	Fill-finish parameters, sterilization, and release methods may matter

The strongest defensible position would combine a new presentation, a technically differentiated formulation, and a narrow but commercially important label. A standalone claim to dextrose-containing buprenorphine injection would likely provide limited protection.

What excipient strategies could improve BUPRENEX?

1. Preserve the dextrose platform

Maintaining dextrose avoids unnecessary clinical and regulatory change. A reformulator could optimize pH, buffer capacity, oxygen control, and container closure while retaining the basic excipient architecture.

This is the lowest-risk strategy for a hospital injectable. It minimizes new excipient exposure and reduces the amount of bridging data needed.

2. Evaluate sodium chloride and alternative tonicity systems

A sodium chloride formulation could simplify manufacturing for facilities already standardized on saline-based injections. It could also improve compatibility with certain infusion protocols.

The tradeoff is that replacing dextrose changes osmolality, ionic strength, chloride exposure, and possibly stability. The product would require comparative data demonstrating equivalent performance and acceptable administration characteristics.

Other candidates, such as mannitol or sorbitol, could provide tonicity adjustment but introduce new risks involving crystallization, degradation, viscosity, or injection tolerability. Their commercial value would depend on a specific advantage, not simple substitution.

3. Develop a buffered formulation

A controlled citrate, acetate, or phosphate buffer could improve pH stability and reduce drift during storage. Buffer selection must account for:

• Buprenorphine solubility across the intended pH range.
• Precipitation after dilution.
• Compatibility with IV fluids.
• Local tolerability after intramuscular injection.
• Interaction with container materials.
• Regulatory acceptability for a chronic or repeated-use setting.

A buffer-based formulation may support formulation patent claims if it produces a demonstrated stability or compatibility advantage.

4. Create a ready-to-administer prefilled syringe

A prefilled syringe is the clearest commercial opportunity. It could reduce dose preparation, needle manipulation, medication waste, and exposure risk for healthcare workers.

The product could be offered as:

• A single-dose glass prefilled syringe.
• A polymer syringe with verified drug-container compatibility.
• A tamper-evident unit-dose syringe.
• A barcode-enabled hospital presentation.
• A needle-free administration system.

The primary technical work would involve extractables and leachables, silicone oil, stopper compatibility, syringe accuracy, plunger break-loose force, and long-term stability.

5. Develop a low-volume concentrated injection

A more concentrated product could reduce injection volume and simplify emergency or postoperative use. The strategy faces a central solubility and dose-accuracy challenge. At higher concentration, small withdrawal errors produce larger dose deviations, and precipitation risk may increase during dilution.

The opportunity is strongest if the product is paired with a calibrated delivery device or fixed-dose syringe.

6. Develop a longer-use or multidose presentation

A multidose vial could reduce packaging waste in high-volume institutions. It would require a preservative strategy or validated aseptic withdrawal system.

Potential preservatives would need careful evaluation because buprenorphine is administered parenterally and may be used in vulnerable patients. Preservatives can create local tolerability and regulatory issues, particularly for intravenous use. A preservative-free multidose system using validated container technology may be more commercially attractive than adding an antimicrobial agent.

What manufacturing and IP barriers affect commercial entry?

The active ingredient is available from multiple pharmaceutical suppliers, but sterile injectable manufacturing remains the principal operational barrier.

Manufacturing risks

• Potent-opioid handling and worker exposure controls.
• Accurate low-dose compounding.
• Sterile filtration and aseptic filling.
• Container-closure integrity.
• Particulate control.
• Extractables and leachables.
• Stability-indicating analytical methods.
• Controlled-substance inventory and reconciliation.
• Reliable supply of compliant glass, elastomers, and syringes.

A manufacturer with a domestic sterile-fill network, established DEA controls, and hospital distribution capacity could compete effectively even without strong patents.

Manufacturing know-how as an advantage

Trade-secret value may arise from:

• Mixing order and hold times.
• pH adjustment procedures.
• Oxygen management.
• Filtration parameters.
• Filling accuracy for small volumes.
• Closure selection.
• Light-protection controls.
• Investigation and control of subvisible particles.

These factors are difficult for patent databases to capture but can determine product availability and hospital acceptance.

Which companies are likely to challenge BUPRENEX commercially?

Competition is expected from generic manufacturers of buprenorphine hydrochloride injection, established injectable suppliers, and companies selling hospital-ready opioid products.

The competitive field includes:

• Hikma, as the BUPRENEX sponsor and an established injectable manufacturer.
• Generic injectable companies with buprenorphine hydrochloride ANDA products.
• Large hospital suppliers with sterile fill-finish capacity.
• Contract development and manufacturing organizations offering prefilled syringes.
• Specialty companies targeting opioid-sparing perioperative care.

The primary competitive variables are price, backorder performance, vial or syringe format, controlled-substance compliance, and hospital purchasing contracts. Patent litigation is less likely to be the principal barrier than regulatory review, manufacturing readiness, and supply reliability.

What generic entry risks exist for BUPRENEX?

Generic entry risk is high because:

1. The drug is a mature small molecule.
2. The dosage form is a conventional sterile solution.
3. The formulation contains common parenteral excipients.
4. There is no meaningful remaining original exclusivity.
5. Clinical use is established.
6. A generic can compete through an ANDA without repeating the full original efficacy program.

A conventional generic vial is the most direct threat. A differentiated prefilled syringe, concentrated product, or modified excipient system may avoid direct price competition, but it would generally require its own regulatory strategy and could face substitution limitations.

How does BUPRENEX compare with alternative buprenorphine products?

Product category	Route	Main use	Excipient opportunity	Competitive position
BUPRENEX injection	IM or slow IV	Acute analgesia	Prefilled syringe, stability, packaging	Mature hospital product
Sublingual buprenorphine	Oral transmucosal	Opioid use disorder	Taste masking, film, dissolution	Different clinical market
Transdermal buprenorphine	Transdermal	Chronic pain	Adhesive, flux control, wear time	Longer-duration delivery
Extended-release injectable buprenorphine	Subcutaneous	Opioid use disorder	Depot matrix, controlled release	Higher formulation complexity
Veterinary buprenorphine injection	Injectable	Animal analgesia	Small-volume packaging, species dosing	Separate regulatory and commercial channel

BUPRENEX does not compete directly with extended-release opioid-use-disorder products on duration or treatment setting. Its opportunity is acute analgesia, particularly where hospitals value rapid administration and controlled dosing.

What commercial opportunities exist for BUPRENEX reformulation?

The most attractive opportunities are ranked below.

Opportunity	Technical difficulty	Patent potential	Commercial attractiveness
Unit-dose prefilled syringe	Moderate	Moderate	High
Ready-to-administer emergency syringe	Moderate	Moderate	High
Improved low-particulate formulation	Moderate	Moderate	Moderate to high
Concentrated injection	High	Moderate	Moderate
Buffered formulation	Moderate	Low to moderate	Moderate
Preservative-free multidose system	High	Moderate	Moderate
New dextrose concentration alone	Low	Low	Low
Alternative tonicity agent alone	Low to moderate	Low	Low

The best business case combines workflow savings with a defendable product claim. A simple excipient swap is unlikely to command a durable premium. A prefilled, tamper-evident, barcoded unit-dose product could support hospital contracting and reduce preparation steps without requiring a novel therapeutic indication.

What litigation and settlement issues affect BUPRENEX?

No major current Paragraph IV litigation or settlement-driven launch constraint is associated with the original BUPRENEX formulation in the public regulatory record typically used for Orange Book analysis. The original product is too mature for its commercial position to depend on an unexpired primary patent.

Future disputes could arise over:

• A patented prefilled syringe.
• A formulation with a defined pH or buffer system.
• A concentrated injection.
• A device-assisted administration method.
• A manufacturing process with a narrow impurity profile.
• Labeling that includes a protected method of use.

Any new formulation patent would need to be listed and litigated under the applicable FDA patent framework only if it met the statutory and regulatory requirements for Orange Book listing.

Key Takeaways

• BUPRENEX uses a simple excipient system based on dextrose, water for injection, and hydrochloric acid for pH adjustment.
• The product has no meaningful remaining original patent or regulatory exclusivity barrier.
• Biosimilar risk is irrelevant because buprenorphine is a small molecule.
• Generic injectable competition is the principal commercial risk.
• The strongest reformulation opportunity is a ready-to-administer, preservative-free prefilled syringe.
• Formulation patents require unexpected stability, compatibility, or administration advantages.
• Sterile fill-finish, opioid handling, container compatibility, and controlled-substance compliance are more important entry barriers than core drug patents.
• A simple excipient substitution is unlikely to create substantial commercial differentiation.
• Device, packaging, workflow, and stability improvements offer better patent and pricing potential than a new tonicity agent alone.

FAQs

Can BUPRENEX be reformulated with sodium chloride instead of dextrose?

Yes, a sodium chloride-based formulation is technically possible, but it would require comparative stability, osmolality, compatibility, particulate, and administration data. The change would not automatically create meaningful patent protection.

Does BUPRENEX contain a preservative?

The labeled BUPRENEX formulation is identified as a preservative-free sterile injection. The product relies on single-dose packaging and aseptic manufacturing rather than an antimicrobial preservative.[1]

Could a prefilled BUPRENEX syringe receive separate FDA approval?

Yes. A materially differentiated prefilled presentation could be developed through an ANDA or 505(b)(2) strategy, depending on the extent of formulation, device, labeling, and clinical differences from the reference product.

What is the strongest excipient patent opportunity for buprenorphine injection?

The strongest opportunity would link a defined excipient and pH system to a measurable technical benefit, such as reduced precipitation after dilution, improved long-term stability, lower particulate formation, or improved recovery from a prefilled syringe.

Is BUPRENEX exposed to biosimilar competition?

No. Buprenorphine hydrochloride is a chemically synthesized small molecule. Competitors enter through generic drug pathways, not the FDA biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2024). BUPRENEX (buprenorphine hydrochloride) injection prescribing information. Hikma Pharmaceuticals USA Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (2019). ANDAs for certain highly purified synthetic peptides. FDA guidance and generic drug approval framework.

5. United States Pharmacopeia. (2024). General chapter <797>: Pharmaceutical compounding - sterile preparations. United States Pharmacopeial Convention.